Quantcast

US Drug Watchdog Now Urges Victims of a Transvaginal Mesh Failure Involving an Unsuccessful Repair Surgery or Erosion to Call Them for the Names of Top Women Lawyers

April 15, 2013

The US Drug Watchdog is offering to help all US women, who are now victim’s of a transvaginal mesh failure involving a unsuccessful surgery to repair the failure, or erosion to call them for the names of best possible attorneys, and the group is promising the attorneys will all be women, because the damages are so gender specific. For more information victims of a severe transvaginal mesh failure in any US state are urged to contact the US Drug Watchdog anytime at 866-714-646. http://USDrugWatchdog.Com

(PRWEB) April 15, 2013

The US Drug Watchdog says, “After talking with at least a thousand victims of a transvaginal mesh failure we are now calling the transvaginal mesh failure issue the absolute worst mess we have ever seen for women, and the damages are literally beyond comprehension. We are also talking about a potentially huge number of US women. According to the New York Times, in 2010, about 185,000 women underwent procedures in which mesh was implanted vaginally to treat urinary incontinence. That is 2010 alone. What we are now trying to do is focus on victims of a transvaginal mesh failure involving a unsuccessful repair surgery, or women who have developed erosion as a result of a transvaginal mesh failure, because we think these women have the worst damages, and we want to get them help.” According to the FDA, “Transvaginal mesh failure occurs when the mesh fails to bind to a woman’s pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. This complication is more commonly referred to as erosion.” The US Drug Watchdog is urging any woman, who has had the transvaginal mesh surgical procedure done, and now has developed severe complications like erosion to call them anytime at 866-714-6466. As part of their initiative the US Drug Watchdog is offering to send all US women, who are victims of a severe transvaginal mesh failure to national caliber attorneys-who are all women. No other group, or organization is offering this service.

The US Drug Watchdog is indicating symptoms of a vaginal mesh implant failure may include:

  • Pain during sexual intercourse caused by erosion.
  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Vaginal Bleeding
  • Vaginal Infection
  • Urinary problems
  • Organ perforation
  • The US Drug Watchdog says, “Transvaginal mesh failures are not limited to one state like as an example California, New York, or Florida. Transvaginal mesh surgical procedures were done in all US States from the biggest by population, to the smallest by population like Wyoming, Maine, South Dakota, or Alaska.” http://USDrugWatchdog.Com

The US Drug Watchdog says, “One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures involving medical devices like the transvaginal mesh failures. If you have a friend, or loved one who is a recipient of a transvaginal mesh that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain severely injured transvaginal mesh failure victims get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal, and we will do our absolute best to make certain all of the attorneys are women.” http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multidistrict litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:

C.R. Bard, Inc., (MDL No. 2187);

American Medical Systems Inc., MDL No. 2325);

Boston Scientific Corp., (MDL No. 2326); and Johnson & Johnson’s Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/4/prweb10620731.htm


Source: prweb



comments powered by Disqus